arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Vivos Therapeutics, Inc.

VVOS
$0.32 0.00 (+0.25%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
27 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
34
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Vivos Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $4.7M
Dividend Yield
Revenue Growth 70.5%
Op. Margin -128.7%
ROIC 1003.0%
FCF / Share $-0.41
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.54
info Valuation on last close. End-of-day price, Aug 7, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.14M
↑ +70.5%
Net Income Profit after all expenses
$-7.68M
↓ -98.8%
Operating Margin Operating profit as % of sales
-128.7%
↑ +22.9% 2th
FCF / Share Free cash flow per share
$-0.41
↑ +9.6%
Long-Term Debt Long-term obligations
$617.00K
↓ -18.1%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
2
Financial Health
63
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters